ClinicalTrials.gg
CompletedNCT00093002Updated Jun 12, 2008

Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer

A Phase 2 interventional study of Fulvestrant in Breast Cancer, sponsored by AstraZeneca. Completed at 32 sites in 6 countries. Open to female participants. Per ClinicalTrials.gov, last updated 2008-06-12.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
179
Allocation
Randomized
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 95 studies testing fulvestrant in Breast Neoplasms — 13 open to participants now, 23 under way, 5 of them phase 3. Fulvestrant · Breast Neoplasms.

Enrollment
27th of 94
179 · median 71
Started
2004
with 9 others
Phase 2
59 of 95
8 open now
Registered
6th of 95
by date
Lead sponsor
18 of 95
AstraZeneca

Among the 95 studies testing fulvestrant in Breast Neoplasms, this one is the 27th largest by enrollment of the 94 interventional ones that give a count, is one of 10 that started in 2004, is one of 59 in phase 2, and was the 6th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

13 of the 95 studies testing fulvestrant in Breast Neoplasms are open now, in 7 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About fulvestrant

Fulvestrant: first FDA approval 2002 (FASLODEX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies testing fulvestrant in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate fulvestrant in the preliminary stage of breast cancer treatment and assess the relationship between dose, exposure, degree of reduction in tumor markers, and efficacy in postmenopausal women with estrogen receptor positive disease.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Early Breast Cancer
  • neoadjuvant therapy
  • hormonal treatment
  • newly diagnosed breast cancer
  • Estrogen Receptor Positive Breast Cancer
  • treatment naïve
  • neoadjuvant treatment
  • neoadjuvant setting
  • invasive breast cancer
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women defined as women who have stopped having menstrual periods
  • Written to participate in the trial
  • confirmation of invasive breast cancer
  • Evidence of hormone sensitivity
  • Willingness to undergo biopsies

Exclusion criteria

Exclusion Criteria:

  • Any previous treatment for breast cancer
  • Unwillingness to stop taking any drug known to affect sex hormonal status or a patient in which it would be inappropriate to stop.
  • Any severe concurrent condition that would preclude surgery or that would jeopardize compliance with the study, e.g., uncontrolled cardiac disease or uncontrolled diabetes mellitus
  • The presence of more than one primary tumor
  • History of to castor oil
  • History of known bleeding disorders
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
179 participants (actual)

Study arms

  • Experimental
    1

    250 mg fulvestrant

    Drug: Fulvestrant

  • Experimental
    2

    500 mg fulvestrant

    Drug: Fulvestrant

Interventions

  • 250 mg \& 500 mg intramuscular injection

    Also known as: FASLODEX™, ZD9238

06

What researchers measure

Primary outcomes

  1. Anti-proliferative effect after 4 weeks of treatment.

Secondary outcomes

  1. Safety, tolerability, tumor response and pharmacokinetics after 4 weeks of treatment.

07

Study locations

32 sites
  • Research Site
    Little Rock, Arkansas, United States
  • Research Site
    Boston, Massachusetts, United States
  • Research Site
    Winchester, Massachusetts, United States
  • Research Site
    Albuquerque, New Mexico, United States
  • Research Site
    Hershey, Pennsylvania, United States
  • Research Site
    Nashville, Tennessee, United States
  • Research Site
    Laredo, Texas, United States
  • Research Site
    Innsbruck, Austria
  • Research Site
    Salzburg, Austria
  • Research Site
    Vienna, Austria
  • Research Site
    Wien, Austria
  • Research Site
    Barretos, Brazil
  • Research Site
    Florianopolis, Brazil
  • Research Site
    Goiamia, Brazil
  • Research Site
    Porto Alegre, Brazil
  • Research Site
    Rio de Janeiro, Brazil
  • Research Site
    Santo Andre, Brazil
  • Research Site
    Sao Paulo, Brazil
  • Research Site
    Berlin, Germany
  • Research Site
    Hannover, Germany
  • Research Site
    Magdeburg, Germany
  • Research Site
    Munchen, Germany
  • Research Site
    Rostock, Germany
  • Research Site
    Bangalore, India
  • Research Site
    Hyderabaad, India
  • Research Site
    New Delhi, India
  • Research Site
    Pune, India
  • Research Site
    Trivandrum, India
  • Research Site
    Birmingham, United Kingdom
  • Research Site
    Bournemouth, United Kingdom
  • Research Site
    Dundee, United Kingdom
  • Research Site
    Edinburgh, United Kingdom
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2004 and a completion of Jul 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2004
First posted
Sep 29, 2004
Start
Jun 2004
CompletionActual
Jul 2007
Last update
Jun 12, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00093002
Lead sponsor
AstraZeneca
First posted
Sep 29, 2004
Start date
Jun 2004
Completion
Jul 2007
Last update
Jun 12, 2008

Study contacts

AstraZeneca Faslodex Medical Science Director, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fulvestrant

Start the discussion